These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 24610632

  • 1. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
    Butt T, Patel PJ, Tufail A, Rubin GS.
    Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632
    [Abstract] [Full Text] [Related]

  • 2. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M, van der Reis MI, Webers CA, Schouten JS.
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC, IVAN Study Investigators.
    BMJ Open; 2014 Jul 29; 4(7):e005094. PubMed ID: 25079928
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H, Li X, Xie F.
    Zhonghua Yan Ke Za Zhi; 2014 Jun 29; 50(6):426-33. PubMed ID: 25241975
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
    Clin Ther; 2008 Dec 29; 30(12):2436-51. PubMed ID: 19167602
    [Abstract] [Full Text] [Related]

  • 9. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct 29; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
    Butt T, Lee A, Lee C, Tufail A, UK AMD EMR Study Group.
    BMJ Open; 2015 May 05; 5(5):e006535. PubMed ID: 25943370
    [Abstract] [Full Text] [Related]

  • 12. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).
    Chakravarthy U, Harding SP, Rogers CA, Downes S, Lotery AJ, Dakin HA, Culliford L, Scott LJ, Nash RL, Taylor J, Muldrew A, Sahni J, Wordsworth S, Raftery J, Peto T, Reeves BC.
    Health Technol Assess; 2015 Oct 05; 19(78):1-298. PubMed ID: 26445075
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.
    Pharmacoeconomics; 2007 Oct 05; 25(10):863-79. PubMed ID: 17887807
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P, Kankaanpää E.
    Acta Ophthalmol; 2016 Nov 05; 94(7):652-656. PubMed ID: 27481048
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
    Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.
    Value Health; 2008 Nov 05; 11(4):563-74. PubMed ID: 18179676
    [Abstract] [Full Text] [Related]

  • 20. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
    Raftery J, Clegg A, Jones J, Tan SC, Lotery A.
    Br J Ophthalmol; 2007 Sep 05; 91(9):1244-6. PubMed ID: 17431015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.